### Program Faculty

#### Sponsorship and CME Credit

#### CME Activity Assessment and Evaluation

### Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference


Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
Roman Perez-Soler

HKI-272 in Non–Small Cell Lung Cancer
Kwok-Kin Wong

Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Mark A. Socinski

Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
Daniel Morgensztern and Ramaswamy Govindan

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Philip D. Bonomi, Lela Buckingham, and John Coon

Bevacizumab in Non–Small Cell Lung Cancer
Alan Sandler

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Emer O. Hanrahan and John V. Heymach

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Gregory J. Riely and Vincent A. Miller

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Bruce E. Johnson, David Jackman, and Pasi A. Jänne

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
Julie E. Bauman, Keith D. Eaton, and Renato G. Martins

The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Jeffrey A. Engelman

Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn

Incorporating Bortezomib into the Treatment of Lung Cancer
Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara

L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Randeep Sangha and Charles Butts